Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 79 out of 100. Prevention and risk

Topic: Risk, prevention and care in population studies

Plain-language summary

Background and objectives Previous randomized controlled trials and longitudinal studies have indicated that ongoing antihypertensive use in late life reduces all-cause dementia risk, but the specific impact on Alzheimer dementia (AD) and non-AD risk remains unclear. Results There were 31,250 participants from 14 nations in the analysis (41% male) with a mean baseline age of 72 (SD 7.5, range 60-110) years. Participants with untreated hypertension had a 36% (hazard ratio [HR] 1.36, 95% CI 1.01-1.83, p = 0.0406) and 42% (HR 1.42, 95% CI 1.08-1.87, p = 0.0135) increased risk of AD compared with "healthy controls" and those with treated hypertension, respectively. Compared with "healthy controls" both those with treated (HR 1.29, 95% CI 1.03-1.60, p = 0.0267) and untreated hypertension (HR 1.69, 95% CI 1.19-2.40, p = 0.0032) had greater non-AD risk, but there was no difference between the treated and untreated groups. Baseline diastolic BP had a significant U-shaped relationship ( p = 0.0227) with non-AD risk in an analysis restricted to those with 5-year follow-up, but otherwise there was no significant relationship between baseline BP and either AD or non-AD risk. Discussion Antihypertensive use was associated with decreased AD but not non-AD risk throughout late life. This suggests that treating hypertension throughout late life continues to be crucial in AD risk mitigation. A single measure of BP was not associated with AD risk, but DBP may have a U-shaped relationship with non-AD risk over longer periods in late life.

What this study adds

Evidence grade: Moderate

This is a pooled review of 31,250 participants. This individual participant data meta-analysis of 31,250 people found that antihypertensive use was associated with decreased Alzheimer dementia risk but not non-Alzheimer dementia risk throughout late life. Reported effect size: Untreated vs treated hypertension: Alzheimer's dementia HR 1.42 (95% CI 1.08-1.87).

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Lennon, M. J., Lipnicki, D. M., Lam, B. C. P., Crawford, J. D., Schutte, A. E., Peters, R., et al. (2024). Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis. Neurology. https://doi.org/10.1212/WNL.0000000000209715

Vancouver

Lennon MJ, Lipnicki DM, Lam BCP, Crawford JD, Schutte AE, Peters R, et al. Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis. Neurology. 2024. doi:10.1212/WNL.0000000000209715. PMID: 39141884.

BibTeX

@article{lennon2024-39141884,
  author  = {Lennon, M. J. and Lipnicki, D. M. and Lam, B. C. P. and Crawford, J. D. and Schutte, A. E. and Peters, R. and others},
  title   = {{Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis}},
  journal = {Neurology},
  year    = {2024},
  doi     = {10.1212/WNL.0000000000209715},
  pmid    = {39141884},
  url     = {https://doi.org/10.1212/WNL.0000000000209715}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This individual participant data meta-analysis of 31,250 people found that antihypertensive use was associated with decreased Alzheimer dementia risk but not non-Alzheimer dementia risk throughout late life. It suggests that treating hypertension in late life remains important for reducing Alzheimer dementia risk, though it does not show a treatment or cure.

Study details

Limitations

Observational cohorts with hypertension history partly self-reported; single baseline BP measurement; residual confounding by indication.

How this study scored 79/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 12 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 77 of the 98 points it could be judged on, which is 79 of 100. Total 79 of 100.77 of the 98 points we could judge = 79 of 100

Published in a leading specialty journal, and it is a meta-analysis pooling many studies. We have no data on free to read, so that was left out: it earned 77 of the 98 points we could judge it on, which is 79 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 4 / 4 31,250 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 4 / 7 Cited 40 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 10.0 citations a year over 4 year(s) since 2024
Impact for its field and year 4 / 6 Cited 10.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 4 other studies in this library
Still being cited 2 / 4 Cited 40 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Perminder Singh Sachdev: h-index 147 (OpenAlex, whole career)
Institution's track record 2 / 3 Imperial College London: institution h-index 1,744 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39141884)
Free to read — / 2 Access not recorded — left out of this score
Points 77 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 77 of the 98 points we could judge it on is 79 out of 100.
Total 79 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Prevention and risk from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →